Company intelligence / Profile preview
Inhibrx
La Jolla, California, United Statesinhibrx.com ↗
- Ownership
- Public · INBX
- Development stage
- Phase 2
01
Overview
Ozekibart (INBRX-109) showed promising results in colorectal adenocarcinoma with one complete response, three partial responses, and six cases of stable disease in a Phase 1 trial. Durable disease control lasting ≥180 days was observed in 46.2% of patients, with a median progression-free survival of 7.85 months. The company is conducting a registration-enabling Phase 2 trial for ozekibart in unresectable or metastatic conventional chondrosarcoma.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Protein therapeuticsBiologic therapeuticsSingle-domain antibody platform
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $1.2B
- Total revenue
- $1.3M
- Enterprise value
- $1.1B
Beyond the preview
Go deeper on Inhibrx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibrx.